FDI Expands Commercial Availability of Blood Test for Mesothelioma

Fujirebio Diagnostics (FDI), a company specializing in oncology testing, and Cisbio international, a French biotechnology company, announced a distribution agreement for European distribution of FDI's new blood test for mesothelioma -- MESOMARK. This agreement, the second for FDI, continues the worldwide commercial rollout of MESOMARK. Earlier this year, FDI launched MESOMARK in Australia where the company signed a contract with an Australian-based distributor.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050414005045&newsLang=en)